Reorganizing the Global Pharmacovigilance Function

An F200 pharma company was reevaluating the operating model of its global drug safety and pharmacovigilance functions. Looking for help assessing cost, quality, and productivity impact of different resourcing scenarios, the group’s head turned to BTG. We delivered an independent pharmacovigilance organization specialist and former engagement lead in Accenture’s life science practice. She worked with internal executives to evaluate the most efficient model, then develop detailed organization-wide communication and implementation plans.